The post Kalohexis doses first patients in 710GO Phase I trial for obesity appeared first on Hospital Management.
Kalohexis doses first patients in 710GO Phase I trial for obesity
Kalohexis has dosed the first patients in its Phase I FIH clinical trial of 710GO, an oral dual MC3R/MC4R agonist to treat general obesity. The post Kalohexis doses first patients in 710GO Phase I trial for obesity appeared first on Hospital Management.
Kalohexis has dosed the first patients in its Phase I FIH clinical trial of 710GO, an oral dual MC3R/MC4R agonist to treat general obesity.
View original source →
